Latest filings (excl ownership)
10-K
2023 FY
Annual report
29 Mar 24
8-K
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
25 Mar 24
8-K
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
21 Mar 24
424B7
Prospectus with selling stockholder info
15 Mar 24
8-K/A
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
6 Mar 24
8-K
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
29 Feb 24
8-K
FDA Issues Reminder of Non-Substitution of PEDMARKÒ (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin
2 Feb 24
EFFECT
Notice of effectiveness
18 Dec 23
CORRESP
Correspondence with SEC
13 Dec 23
8-K
Fennec Announces Incremental $5 Million Investment from Petrichor
5 Dec 23
UPLOAD
Letter from SEC
28 Nov 23
S-3
Shelf registration
9 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Fennec Pharmaceuticals Announces Third Quarter 2023
6 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
8-K/A
Fennec Pharmaceuticals Announces Second Quarter 2023
7 Aug 23
8-K
Fennec Pharmaceuticals Announces Second Quarter 2023
4 Aug 23
8-K
Fennec Pharmaceuticals Announces Second Quarter 2023
4 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
12 Jun 23
8-K
Other Events
6 Jun 23
10-Q
2023 Q1
Quarterly report
12 May 23
DEF 14A
Definitive proxy
28 Apr 23
8-K
Other Events
4 Apr 23
10-K
2022 FY
Annual report
29 Mar 23
8-K
Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA
31 Jan 23
8-K
Other Events
25 Jan 23
424B3
Prospectus supplement
15 Dec 22
EFFECT
Notice of effectiveness
13 Dec 22
CORRESP
Correspondence with SEC
8 Dec 22
UPLOAD
Letter from SEC
7 Dec 22
S-3
Shelf registration
1 Dec 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
Fennec Pharmaceuticals Announces Commercial Availability of PEDMARK® (sodium thiosulfate injection) in the United States
17 Oct 22
8-K
Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment
26 Sep 22
8-K
Other Events
21 Sep 22
8-K
Fennec Pharmaceuticals Closes First $5 Million Investment
22 Aug 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
8-K
Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor
1 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 22
10-Q
2022 Q1
Quarterly report
12 May 22
Latest ownership filings
4/A
Adrian Haigh
26 Apr 24
4/A
Adrian Haigh
26 Apr 24
4
Adrian Haigh
22 Apr 24
144
Notice of proposed sale of securities
22 Apr 24
144
Notice of proposed sale of securities
19 Apr 24
4
Adrian Haigh
18 Apr 24
144
Notice of proposed sale of securities
18 Apr 24
144
Notice of proposed sale of securities
17 Apr 24
4
Adrian Haigh
16 Apr 24
144
Notice of proposed sale of securities
16 Apr 24
4
CHRIS A RALLIS
15 Apr 24
144
Notice of proposed sale of securities
15 Apr 24
4
Rosty Raykov
5 Apr 24
144
Notice of proposed sale of securities
5 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
4
Rosty Raykov
3 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
4
Robert Andrade
3 Apr 24
4
Rosty Raykov
3 Apr 24
4
CHRIS A RALLIS
27 Mar 24
4
Robert Andrade
27 Mar 24
144
Notice of proposed sale of securities
26 Mar 24
4
Robert Andrade
25 Mar 24
144
Notice of proposed sale of securities
25 Mar 24
SC 13G
Solas Capital Management, LLC
14 Feb 24
4
Robert Andrade
5 Jan 24
144
Notice of proposed sale of securities
5 Jan 24
144
Notice of proposed sale of securities
4 Jan 24
4
Rosty Raykov
29 Dec 23
4
CHRIS A RALLIS
28 Dec 23
144
Notice of proposed sale of securities
28 Dec 23
4
CHRIS A RALLIS
20 Nov 23
4
Khalid Islam
16 Nov 23
4
Rosty Raykov
9 Nov 23
144
Notice of proposed sale of securities
8 Nov 23
4
Rosty Raykov
3 Nov 23
4
CHRIS A RALLIS
18 Aug 23
144
Notice of proposed sale of securities
18 Aug 23
4
Adrian Haigh
7 Aug 23
4
CHRIS A RALLIS
24 Jul 23